Navigation Links
endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
Date:6/22/2012

San Francisco, CA (PRWEB) June 22, 2012

Today, endpoint (http://www.endpointclinical.com) is proud to announce that they have adopted RealityCorp’s ClinTest Voice. ClinTest Voice offers clients a dynamic, easy to use, solution for IVR test automation in a fast-paced, ever-changing industry. endpoint’s PULSE, in combination with RealityCorp’s ClinTest Voice, provides endpoint’s clients with industry leading technology, reliability, and development timelines.

“After utilizing ClinTest Voice in our environment for the last six months, it became apparent that this product would change the face of how IVR validation is performed. Testers are still responsible for creating test scripts, just like the manual process; however, that is where the similarities stop and the time savings begin. With ClinTest Voice we are able to rapidly create test scripts, including modules as dynamic as Randomization, and automate many aspects of our IVR testing in an environment where time is money. The adoption of ClinTest allows us to further leverage the rapid development of the endpoint PULSE product while providing endpoint’s Clients with the most robust objective evidence in the industry. ClinTest Voice produces objective evidence output document with embedded real-time recordings of individual prompts at the test step level, allowing users or auditors to quickly navigate to the desired test step and hear what was said by PULSE” said Jonathan Ball, Director of Testing at endpoint.

The automation of eClinical software is the next technology phase for the clinical industry. After thorough due diligence, endpoint has adopted RealityCorp’s automation solution to accurately and, more importantly, safely validate their IVR systems. With the demanding deadlines and multitude of changes from study to study, preparation of automation scripts has always been a challenge for IVR systems; however, RealityCorp’s ClinTest Voice offers endpoint a rapidly configurable way to create test scripts in an exceptionally user friendly product. The expectation that endpoint set for success criteria during their trial phase was simple; be able to save several days in testing to provide our Clients even faster turn around times and create a more consistent, bug free product to our End Users. endpoint was able to achieve this with the added benefit of the ClinTest Voice’s objective evidence documentation.

RealityCorp’s ClinTest Voice has made automated testing possible within the Clinical Trial space by:

  •     Allowing test engineers to create easy to use, configurable test scripts for even the most dynamic randomization or drug dispensation scenarios.
  •     Offering the testing team the option to never have to dial into the IVR again.
  •     Producing accurate, relevant testing objective evidence that is comprehendible at any level.
  •     Provide the most robust objective evidence by fully integrating with the associated IVR Database, providing maximum visibility for all validation activities – including data setup

About endpoint
endpoint is an innovative company dedicated to the development of the leading Integrated Voice Response (IVR/IWR) technology platforms for the life sciences industry. endpoint’s founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations.

Read the full story at http://www.prweb.com/releases/2012/6/prweb9630085.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
2. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
3. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
4. Positive Clinical Study Results for BSPs HyperQ Technology
5. Arizona State University engineers aim to improve performance of technology in extreme environments
6. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
7. Pitt discoveries in quantum physics could change face of technology
8. Verenium to Present at Baird Clean Technology Conference
9. Puma Biotechnology Announces Completion of Private Placement
10. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
11. Animal Biotechnology - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):